Scholar Rock (SRRK) valuation after FDA manufacturing update and apitegromab resubmission plans [Yahoo! Finance]
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Scholar Rock (NASDAQ:SRRK) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Scholar Rock (NASDAQ:SRRK) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $47.00. They now have an "overweight" rating on the stock.
Scholar Rock (NASDAQ:SRRK) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $42.00 price target on the stock.